This four-part series will assess four assumptions about the HTA process and market access and reveal how each is a misconception that could derail the market access process for biotechnology companies. Find out more here. (Source: Context Matters, 5/4/17) […]
RWD Differences Across 6 European HTAs
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR)'s Value in Health recently published a new study revealing notable differences in how European health technology assessment (HTA) agencies assess real-world data. Find out more here. (Source: ISPOR) […]
HTA Evaluation in Australia, Canada, England and Scotland
The national regulatory, health technology assessment (HTA), and reimbursement pathways for public health care in Australia, Canada, England, and Scotland, were evaluated to identify factors for differing national HTA recommendations between the four agencies. Read more here. (Source: Value in […]
NICE Brings HTA to Mobile Health Apps
The National Institute for Health and Care Excellence (NICE) is planning to apply its healthcare technology assessment (HTA) experience to health- focused mobile applications. Find out more here. (Source: Rebecca Clifford, PMLiVE, 2/2/17) […]
ISPOR Responds to a United EU Focus on HTA
After sending out a survey to members and going through the responses, The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has submitted a formal response to the European Commission's launch of a public consultation on the Commission initiative for strengthening EU […]
Report Calls for New Approach to Rising Drug Prices
“...The OECD urges that schemes to promote quicker access to promising therapeutics for severe unmet needs ought not to compromise patient safety. In addition, regulation of new technology types, particularly hybrid technologies, should be better coordinated between bodies with diverse regulatory […]
Working Towards a Harmonized European HTA System
The fragmented European approach to assessing the value of new medicines has been difficult for companies to navigate. However, the Federation of European research-based drug firms (EFPIA) is hoping to harmonize the European health technology assessment (HTA) and plans on making some firm proposals […]
4 Reasons Why the U.S. Rejects the European Healthcare Approach
It's clear the American healthcare system has long been in need of a total and complete overhaul. Many look to other countries who have succeeded in healthcare reform, however, others are calling for a distinctly American approach. What would that look like? Why is America so against the European, […]
Uncertainties Become Barriers to Pharmaceutical Value-Based Agreements
Interviews were conducted with five stakeholders regarding their experience with value-based agreements (VBAs) and identified three key barriers and possible solutions. Find out more here. (Source: HealthAffairsBlog, 11/4/16) […]
Pricing & Market Access Strategies for Orphan Drugs
Orphan Drugs: Pricing and Market Access Strategies is an expert, FirstWord report that reveals the latest thinking on the proven strategic approaches that will deliver market access and pricing success in the increasingly complex and challenging US and EU5 orphan drug sector. Available for purchase […]
